Home » Healthcare » Pharmaceuticals » Japan Contract Pharmaceutical Manufacturing Market

Japan Contract Pharmaceutical Manufacturing Market By Service Type (Contract Manufacturing Organization (CMO), API Manufacturing, Final Dosage Form Manufacturing, Packaging, Contract Research Organization (CRO), Drug Discovery, Preclinical Studies, Early Phase I-IIa, Phase IIa-III, Phase IIIb-IV, Medical Coding and Writing, Monitoring, Clinical Data Management, Others (Protocol Development, etc.)); By Molecule Type (Small Molecule, Large Molecule) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Japan Contract Pharmaceutical Manufacturing Market Size 2023	USD 17,246.92 million
Japan Contract Pharmaceutical Manufacturing Market, CAGR	8.83
Japan Contract Pharmaceutical Manufacturing Market Size 2032	USD 36,963.23 million

Market Overview

The Japan Contract Pharmaceutical Manufacturing Market is projected to grow from USD 17,246.92 million in 2023 to USD 36,963.23 million by 2032, at a CAGR of 8.83%.

The Japan Contract Pharmaceutical Manufacturing market is driven by the increasing demand for cost-effective and high-quality drug production solutions. The growing outsourcing trend among pharmaceutical companies, coupled with Japan’s advanced technological infrastructure and skilled workforce, has accelerated market growth. Additionally, the rising need for biopharmaceutical manufacturing and the expansion of contract manufacturing organizations (CMOs) are pivotal factors contributing to market expansion. The country’s strong regulatory framework and adherence to international quality standards further enhance its attractiveness as a manufacturing hub. Trends such as the adoption of advanced manufacturing technologies, including continuous manufacturing and biotechnological advancements, are also gaining traction, improving production efficiency and reducing costs. Furthermore, the market is benefiting from the growing demand for personalized medicines, which require specialized manufacturing processes. These factors, combined with Japan’s strategic position in the Asia-Pacific region, make it a key player in the global contract pharmaceutical manufacturing market.

Japan’s Contract Pharmaceutical Manufacturing market is concentrated in regions like Kanto, Kansai, Chubu, and Kyushu, each contributing significantly to the sector’s growth. The Kanto region, with Tokyo as its hub, is home to many leading pharmaceutical companies and contract manufacturing organizations (CMOs) and Contract Research Organizations (CROs), offering a wide range of services from API manufacturing to clinical trial support. Key players in the Japanese market include Lonza Group, Fuji Pharma Co., Ltd., Kaken Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, and Eisai Co., Ltd. These companies play a crucial role in driving innovation and ensuring high-quality production processes. The presence of numerous specialized CMOs and CROs across these regions allows for efficient outsourcing solutions, helping pharmaceutical companies reduce costs while meeting stringent regulatory requirements. This geographic distribution, coupled with the expertise of the key players, strengthens Japan’s position as a global leader in pharmaceutical manufacturing.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights

The Japan Contract Pharmaceutical Manufacturing market was valued at USD 17,246.92 million in 2023 and is projected to reach USD 36,963.23 million by 2032, growing at a CAGR of 8.83%.
The aging population in Japan is driving the demand for pharmaceutical products, leading to increased outsourcing of manufacturing operations.
Rising healthcare costs and the need for cost-efficient solutions are pushing pharmaceutical companies to partner with contract manufacturers.
Technological advancements, such as automation and AI, are enhancing the efficiency and accuracy of manufacturing processes.
Strict regulatory standards in Japan are challenging manufacturers but also ensuring high product quality, driving demand for specialized CMOs and CROs.
Intense competition from both domestic and global players is a key factor influencing pricing and service offerings in the market.
The Kanto region dominates the market, followed by Kansai and Chubu, with increasing activity in biopharmaceutical manufacturing across Japan.

Market Drivers

Aging Population

Japan has one of the world’s oldest populations, with a significant rise in age-related chronic diseases like diabetes, cancer, and cardiovascular conditions. As the elderly population grows, the demand for medications to manage these health issues has surged. This increased need for pharmaceuticals is driving the demand for efficient, cost-effective manufacturing solutions. Contract pharmaceutical manufacturers are well-positioned to meet these growing needs by providing specialized services that enable faster and more affordable production of necessary treatments.

Rising Healthcare Costs

With healthcare costs rising globally, pharmaceutical companies are increasingly outsourcing their manufacturing operations to contract manufacturers in Japan. These manufacturers offer economies of scale, specialized expertise, and operational efficiencies that help companies lower their production expenses. For instance, Japan’s healthcare expenditures reached a record ¥44.2 trillion in fiscal 2021. By outsourcing, pharmaceutical firms can focus on their core competencies, such as drug development, while leveraging the cost advantages of established contract manufacturers who have the capacity to handle large volumes efficiently.

Strict Regulatory Environment

Japan’s stringent regulatory standards, including adherence to Good Manufacturing Practices (GMP) and other quality control measures, ensure the highest standards for pharmaceutical production. Contract manufacturers with proven expertise in navigating these complex regulations provide significant value by helping pharmaceutical companies maintain compliance while meeting the high-quality standards expected in Japan. For instance, the Pharmaceuticals and Medical Devices Agency (PMDA) conducts regular GMP compliance inspections to ensure adherence to these standards. These manufacturers’ ability to manage regulatory challenges effectively makes them key partners for pharmaceutical companies seeking to enter or expand in the Japanese market.

Technological Advancements and Government Initiatives

Advancements in technology, such as automation, robotics, and artificial intelligence, are revolutionizing the pharmaceutical manufacturing sector in Japan. Contract manufacturers who invest in these technologies can improve operational efficiency, reduce errors, and accelerate the time-to-market for new drugs. For instance, Japanese researchers are making notable progress in pharmaceutical applications of nanomaterials and nanotechnology. Moreover, the Japanese government’s initiatives, including tax incentives and streamlined regulatory processes, further support the pharmaceutical industry’s growth. These favorable conditions provide contract manufacturers with the opportunity to expand their operations, making Japan an increasingly attractive location for pharmaceutical production.

Market Trends

Aging Population and Increased Healthcare Demand

Japan’s aging population is one of the key drivers of the country’s pharmaceutical industry. As one of the world’s oldest populations, Japan faces a rise in chronic diseases such as diabetes, cancer, and cardiovascular conditions, which require ongoing medication and treatment. For instance, approximately 30% of Japan’s population was aged 65 years and above in 2022. This demographic shift is creating an increased demand for pharmaceuticals, presenting significant opportunities for contract manufacturers to scale production and meet the growing healthcare needs. Contract manufacturers can play a crucial role in helping pharmaceutical companies efficiently address this rising demand by providing the necessary infrastructure and expertise for large-scale drug production.

Rising Healthcare Costs and Cost-Efficiency

The global pharmaceutical industry is under significant pressure to reduce costs while maintaining the highest quality standards. With the rising costs of healthcare, pharmaceutical companies are increasingly outsourcing manufacturing operations to contract manufacturers in Japan. This outsourcing allows companies to take advantage of economies of scale, reducing overall production costs without compromising product quality. Contract manufacturers, with their specialized expertise and established infrastructure, can deliver cost-efficient solutions, enabling pharmaceutical companies to remain competitive in a challenging economic environment. The ability to outsource complex manufacturing processes to experienced contractors also allows pharmaceutical companies to focus on their core activities, such as drug development and marketing.

Strict Regulatory Environment and Quality Focus

Japan has one of the most stringent regulatory environments for pharmaceutical manufacturing, ensuring the safety, efficacy, and quality of drugs produced in the country. The Japanese regulatory framework includes strict adherence to Good Manufacturing Practices (GMP) and other quality control measures. This high level of scrutiny has created a demand for contract manufacturers with strong quality management systems and expertise in navigating Japan’s complex regulatory landscape. Manufacturers who can ensure compliance with these standards are in high demand, as pharmaceutical companies need partners they can trust to meet the rigorous regulatory requirements. The focus on quality assurance and regulatory compliance is a critical trend driving the need for specialized contract manufacturers in Japan.

Technological Advancements and Innovation

Technological advancements are reshaping the pharmaceutical manufacturing landscape in Japan. The adoption of digital technologies, including automation, robotics, and artificial intelligence, is enhancing operational efficiency, improving productivity, and reducing human error in the manufacturing process. Contract manufacturers who invest in these cutting-edge technologies are better equipped to meet the evolving needs of the pharmaceutical industry, delivering faster, more accurate, and cost-effective solutions. Additionally, contract manufacturers are investing in research and development to innovate and develop advanced manufacturing processes and technologies. This innovation is not only improving production capabilities but also enabling manufacturers to support the development of new and complex therapies, including biologics and personalized medicines. As a result, technological innovation is a key trend driving the growth of the contract pharmaceutical manufacturing market in Japan.

Market Challenges Analysis

Regulatory and Compliance Challenges

Japan’s pharmaceutical manufacturing sector faces significant challenges due to its stringent regulatory environment, which includes some of the world’s most rigorous standards. Navigating the complex approval processes for drug production and distribution can be difficult for both domestic and international companies. Frequent changes to regulations further complicate the landscape, requiring companies to stay up-to-date and constantly adapt to new compliance requirements. These regulatory hurdles create additional costs and administrative burdens for contract manufacturers, who must ensure they meet the evolving standards while maintaining operational efficiency. As the industry grows and demands for advanced therapies rise, staying compliant with these stringent regulations remains a significant challenge for manufacturers operating in Japan.

Labor Shortages and High Operational Costs

Japan’s aging population and declining birth rates have led to a shrinking workforce, especially in skilled manufacturing roles critical for the pharmaceutical sector. The scarcity of qualified workers, particularly in specialized fields like biotechnology and pharmaceuticals, poses significant challenges for companies trying to maintain a highly skilled labor force. For instance, the unemployment rate in Japan is expected to fall below 2% in 2024, indicating a severe labor shortage. Attracting and retaining talent in this environment is becoming increasingly difficult, creating a strain on contract pharmaceutical manufacturers to maintain production standards. Additionally, high operational costs further exacerbate this issue. Urban areas, where most manufacturing facilities are located, face elevated land and labor costs, significantly impacting the overall expenses of pharmaceutical companies. The costs of infrastructure and utilities, including electricity and water, can be higher than in other regions, increasing the operational burden. These factors, combined with the need to address labor shortages, make it challenging for contract manufacturers to remain competitive, especially in the face of global competition and economic fluctuations.

Market Opportunities

Expanding Biopharmaceutical Market

Japan’s growing demand for biologics presents a significant opportunity for contract pharmaceutical manufacturers. With the increasing prevalence of chronic diseases and aging-related conditions, the need for biologic drugs such as monoclonal antibodies and vaccines is expanding. Contract manufacturers with specialized capabilities in biopharmaceuticals are well-positioned to tap into this market, providing production solutions for these complex and high-demand therapies. The rise of personalized medicine further enhances this opportunity, as customized treatments require specialized manufacturing processes that contract manufacturers can offer. By investing in advanced technologies and developing expertise in biologics, contract manufacturers can not only meet the evolving needs of the Japanese healthcare sector but also become key players in the global biopharmaceutical market.

Government Support and Infrastructure Development

The Japanese government has implemented several initiatives to support the growth of the pharmaceutical industry, offering tax incentives and streamlining regulatory processes to attract investment. These favorable conditions present a significant opportunity for contract manufacturers to expand their operations in Japan. The government’s focus on innovation, coupled with Japan’s advanced infrastructure, makes the country an ideal location for pharmaceutical manufacturing. Moreover, the ongoing digital transformation in the sector, including the adoption of automation and artificial intelligence, presents opportunities for contract manufacturers to enhance operational efficiency and reduce costs. These advancements, combined with Japan’s commitment to supporting the pharmaceutical sector, offer promising growth prospects for contract manufacturers looking to establish or expand their presence in the region.

Market Segmentation Analysis:

By Service Type:

The Japan Contract Pharmaceutical Manufacturing market is segmented into two primary categories: Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs). CMOs are further divided into key service areas, including Active Pharmaceutical Ingredient (API) manufacturing, final dosage form manufacturing, and packaging. These segments cater to the growing demand for efficient, high-quality production and packaging of pharmaceutical products. API manufacturing remains a significant driver due to the increasing demand for specialized ingredients, while final dosage form manufacturing and packaging play crucial roles in ensuring product availability and compliance with regulatory standards. On the other hand, CROs offer a wide range of services that support drug development processes. This includes drug discovery, preclinical studies, and various phases of clinical trials (Phases I-IV), as well as specialized services like medical coding, clinical data management, and protocol development. The role of CROs has expanded with the growing complexity of clinical trials and the need for advanced research solutions, providing pharmaceutical companies with comprehensive support throughout the drug development lifecycle.

By Molecule Type:

In terms of molecule types, the market is primarily divided into small molecules and large molecules. Small molecules are the most prevalent, accounting for a significant share of contract pharmaceutical manufacturing. These molecules are used in a wide variety of therapies and are often associated with traditional drug formulations. The manufacturing process for small molecules is well-established, and demand remains strong as the pharmaceutical industry continues to develop new generics and branded drugs. Large molecules, particularly biologics, are experiencing rapid growth due to their increasing use in treating complex diseases such as cancer and autoimmune disorders. This segment requires specialized manufacturing processes, which contract manufacturers with advanced biotechnological capabilities can provide. As the demand for biologics rises, the need for contract manufacturers skilled in producing large molecules is expected to continue expanding, offering significant opportunities for growth in this segment of the market.

Segments:

Based on Service Type:

Contract Manufacturing Organization (CMO)
API Manufacturing
Final Dosage Form Manufacturing
Packaging
Contract Research Organization (CRO)
Drug Discovery
Preclinical Studies
Early Phase I-IIa
Phase IIa-III
Phase IIIb-IV
Medical Coding and Writing
Monitoring
Clinical Data Management
Others (Protocol Development, etc.)

Based on Molecule Type:

Small Molecule
Large Molecule

Based on the Geography:

Kanto Region
Kansai Region
Chubu Region
Kyushu Region
Other Regions

Regional Analysis

Kanto region

The Kanto region, which includes Tokyo, the capital city of Japan, and its surrounding areas, accounts for approximately 40% of the total market share in the Japan Contract Pharmaceutical Manufacturing sector. This significant share can be attributed to the region’s dynamic and robust economic environment, which fosters business growth and innovation. Kanto is home to many of Japan’s largest pharmaceutical companies, leading research institutions, and cutting-edge healthcare facilities. The region’s strong infrastructure, coupled with its advanced technological capabilities, creates an ideal ecosystem for pharmaceutical research, development, and manufacturing.

Kansai Region

The Kansai region, home to cities like Osaka and Kyoto, holds the second-largest share of the contract pharmaceutical manufacturing market in Japan, contributing around 25%. This region is renowned for its strong pharmaceutical and biotechnology industries, supported by its strategic location, advanced manufacturing infrastructure, and growing number of CROs and CMOs. The Kansai region is increasingly attracting investment in contract manufacturing due to its focus on innovation and research in the pharmaceutical sector, as well as its competitive operational costs compared to the Kanto region. The growing demand for biologics and small molecule drugs in this region further strengthens its position in the market.

Chubu Region

The Chubu region, which includes Nagoya, is an important hub for pharmaceutical manufacturing, accounting for approximately 20% of the market share. This region has been increasingly recognized for its manufacturing excellence, particularly in automotive and industrial sectors, which has positively influenced pharmaceutical manufacturing capabilities as well. Companies in the Chubu region benefit from the area’s well-established infrastructure, advanced manufacturing technology, and skilled labor force. The demand for contract pharmaceutical manufacturing services in Chubu has been growing steadily due to an increased focus on both generic drugs and the emerging biologics sector. Additionally, the region’s favorable business environment and governmental incentives contribute to its expanding market presence.

Kyushu Region

The Kyushu region, located in the southern part of Japan, holds around 10% of the market share in the contract pharmaceutical manufacturing sector. Kyushu’s pharmaceutical manufacturing industry is bolstered by its cost advantages and proximity to major Asian markets, making it an attractive location for international pharmaceutical companies seeking efficient production capabilities. The region is also witnessing growth in the biopharmaceutical sector, with several contract manufacturers expanding their operations. Other regions, collectively contributing about 5% of the market, also play a role in the broader pharmaceutical manufacturing landscape. These areas are home to niche manufacturers and serve smaller markets but still contribute to the overall diversification and growth of Japan’s contract pharmaceutical manufacturing sector.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Lonza Group
Fuji Pharma Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Ajinomoto Co., Inc.
CMIC Group
Sumitomo Dainippon Pharma Co., Ltd.
Nichirei Corporation

Competitive Analysis

The Japan Contract Pharmaceutical Manufacturing market is highly competitive, with several established players providing a wide range of services, including contract manufacturing and research. Leading companies such as Lonza Group, Fuji Pharma Co., Ltd., Kaken Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Ajinomoto Co., Inc., CMIC Group, Sumitomo Dainippon Pharma Co., Ltd., and Nichirei Corporation dominate the market. Companies in this market differentiate themselves through their technological capabilities, expertise, and adherence to stringent regulatory standards. With the rising demand for specialized services, many companies focus on offering end-to-end solutions, including Active Pharmaceutical Ingredient (API) manufacturing, final dosage form production, and packaging. Additionally, companies are increasingly investing in automation, artificial intelligence, and digital technologies to enhance operational efficiency, reduce errors, and accelerate drug development timelines. For example, Takeda is investing approximately ¥100 billion in a new plasma-derived therapies manufacturing facility in Osaka, which will feature advanced automation and digital technologies. The market is also characterized by fierce competition in the biopharmaceutical sector, with contract manufacturers specializing in biologics such as monoclonal antibodies and vaccines. The ability to meet complex regulatory requirements and ensure high product quality has become a key differentiator. Moreover, players in the market must navigate the challenges posed by high operational costs, particularly in urban areas, and the need to stay ahead of global competitors offering lower-cost services. This competitive landscape compels companies to focus on innovation, cost management, and continuous process improvement to maintain their market positions.

Recent Developments

In July 2024, Esteve Pharmaceuticals announced an investment of USD 108 million to build a new manufacturing unit at its Girona plant for API production.
In May 2024, AbbVie entered into a product development and option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric disorders.
In May 2024, Siren Biotechnology and Catalent, Inc. entered in partnership for manufacturing of AAV Gene Therapies for cancer.
In April 2024, KVK-Tech entered into a strategic agreement with Sen-Jam Pharmaceutical to manufacture the latter’s injectable anti-inflammatory therapeutic, SJP-100.
In March 2024, Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion in cash.
In November 2023, Daré Bioscience, Inc., a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and consulting company, announced that the companies extended their partnership agreement under which Premier Research International, LLC will continue to provide an exclusive basis contract research organization (CRO) service within the U.S. to support the clinical development of Daré Bioscience, Inc’s reproductive health portfolio
In November, 2023, Ichor Life Sciences, a full-service contract research organization (CRO) and longevity biotechnology company, announced the launch of Ichor Clinical Trial Services. With the founding of Ichor Clinical, the company is able to serve biotechnology and pharmaceutical clients from early preclinical studies through late-stage clinical trials and U.S. Food Drug Administration approval.

Market Concentration & Characteristics

The Japan Contract Pharmaceutical Manufacturing market is moderately concentrated, with a mix of large multinational corporations and smaller, specialized players. The market is characterized by a high level of expertise and specialization, with contract manufacturers offering a broad spectrum of services, from Active Pharmaceutical Ingredient (API) production to final dosage form manufacturing and packaging. These companies are often highly focused on adhering to stringent regulatory standards, such as Good Manufacturing Practices (GMP), ensuring the highest quality and safety in pharmaceutical products. Another key characteristic of the market is the growing demand for biopharmaceutical manufacturing, as the sector sees a significant rise in biologics and biosimilars, such as monoclonal antibodies and vaccines. This trend is encouraging contract manufacturers to invest in specialized technologies and advanced manufacturing processes. The competitive environment in Japan is shaped by the constant push for technological innovation, with many players adopting automation, robotics, and artificial intelligence to streamline operations and reduce time-to-market. While larger firms dominate the market share, smaller contract manufacturers often find their niche by offering specialized services or focusing on high-quality, customized manufacturing solutions. Overall, the market is driven by a balance of both established players and new entrants that are able to adapt to evolving industry trends and regulatory requirements.

Report Coverage

The research report offers an in-depth analysis based on Service Type, Molecule Type, and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Japan Contract Pharmaceutical Manufacturing market is expected to continue its strong growth, driven by an aging population and increased healthcare demand.
The rising demand for biologics and biosimilars will likely lead to further specialization in biopharmaceutical manufacturing services.
Companies will increasingly adopt advanced technologies like automation, artificial intelligence, and robotics to improve operational efficiency and reduce errors.
Outsourcing of manufacturing services will grow as pharmaceutical companies seek cost-effective solutions to manage rising production costs.
Regulatory compliance and quality assurance will remain a top priority, with companies focusing on meeting Japan’s stringent standards.
The market will see a shift towards digitalization and data-driven approaches to enhance production and streamline drug development processes.
The demand for high-quality generic drugs will continue to rise, encouraging contract manufacturers to offer cost-effective production solutions.
Japan’s strong healthcare infrastructure will attract more foreign investments in contract manufacturing, further expanding market opportunities.
Competition in the market will intensify, with global players offering lower-cost solutions, pushing local firms to innovate and improve their services.
Government initiatives and policy support will likely continue to create a favorable environment for contract manufacturers in Japan.

CHAPTER NO. 1 : INTRODUCTION 18

1.1. Report Description 18

Purpose of the Report 18

USP & Key Offerings 18

1.2. Key Benefits for Stakeholders 18

1.3. Target Audience 19

1.4. Report Scope 19

CHAPTER NO. 2 : EXECUTIVE SUMMARY 20

2.1. Japan Contract Pharmaceutical Manufacturing Market Snapshot 20

2.2. Japan Contract Pharmaceutical Manufacturing Market, 2018 – 2032 (USD Million) 21

CHAPTER NO. 3 : JAPAN CONTRACT PHARMACEUTICAL MANUFACTURING MARKET – INDUSTRY ANALYSIS 22

3.1. Introduction 22

3.2. Market Drivers 23

3.3. Increasing Aging Population 23

3.4. Rising Demand for Generic Drugs 24

3.5. Market Restraints 25

3.6. Rising Competition and Price Pressures 25

3.7. Market Opportunities 26

3.8. Market Opportunity Analysis 26

3.9. Porter’s Five Forces Analysis 27

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 28

4.1. Company Market Share Analysis – 2023 28

4.1.1. Japan Contract Pharmaceutical Manufacturing Market: Company Market Share, by Volume, 2023 28

4.1.2. Japan Contract Pharmaceutical Manufacturing Market: Company Market Share, by Revenue, 2023 29

4.1.3. Japan Contract Pharmaceutical Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 29

4.1.4. Japan Contract Pharmaceutical Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 30

4.2. Japan Contract Pharmaceutical Manufacturing Market Company Revenue Market Share, 2023 31

4.3. Company Assessment Metrics, 2023 32

4.3.1. Stars 32

4.3.2. Emerging Leaders 32

4.3.3. Pervasive Players 32

4.3.4. Participants 32

4.4. Start-ups /SMEs Assessment Metrics, 2023 32

4.4.1. Progressive Companies 32

4.4.2. Responsive Companies 32

4.4.3. Dynamic Companies 32

4.4.4. Starting Blocks 32

4.5. Strategic Developments 33

4.5.1. Acquisitions & Mergers 33

New Product Launch 33

4.6. Key Players Product Matrix 34

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 35

5.1. PESTEL 35

5.1.1. Political Factors 35

5.1.2. Economic Factors 35

5.1.3. Social Factors 35

5.1.4. Technological Factors 35

5.1.5. Environmental Factors 35

5.1.6. Legal Factors 35

5.2. Adjacent Market Analysis 35

CHAPTER NO. 6 : JAPAN CONTRACT PHARMACEUTICAL MANUFACTURING MARKET – BY SERVICE TYPE SEGMENT ANALYSIS 36

6.1. Japan Contract Pharmaceutical Manufacturing Market Overview, by Service Type Segment 36

6.1.1. Japan Contract Pharmaceutical Manufacturing Market Revenue Share, By Service Type, 2023 & 2032 37

6.1.2. Japan Contract Pharmaceutical Manufacturing Market Attractiveness Analysis, By Service Type 38

6.1.3. Incremental Revenue Growth Opportunity, by Service Type, 2024 – 2032 38

6.1.4. Japan Contract Pharmaceutical Manufacturing Market Revenue, By Service Type, 2018, 2023, 2027 & 2032 39

6.2. Contract Manufacturing Organization (CMO) 40

6.2.1. Japan Contract Manufacturing Organization (CMO) Japan Contract Pharmaceutical Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 41

6.2.2. Japan Contract Manufacturing Organization (CMO) Japan Contract Pharmaceutical Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 41

6.2.3. API Manufacturing 42

6.2.4. Final dosage form manufacturing 43

6.2.5. Packaging 44

6.3. Contract Research Organization (CRO) 45

6.3.1. Drug Discovery 46

6.3.2. Preclinical Studies 47

6.3.3. Early Phase I-Ila 48

6.3.4. Phase IIa-III 49

6.3.5. Phase IIIb-IV 50

6.3.6. Medical Coding and Writing 51

6.3.7. Monitoring 52

6.3.8. Clinical Data Management 53

6.3.9. Others (Protocol Development, etc.) 54

CHAPTER NO. 7 : CONTRACT PHARMACEUTICAL MANUFACTURING MARKET – ANALYSIS 55

7.1.1. Japan Contract Pharmaceutical Manufacturing Market Revenue, By Service Type, 2018 – 2023 (USD Million) 55

7.1.2. Japan Contract Pharmaceutical Manufacturing Market Revenue, By Molecule Type, 2018 – 2023 (USD Million) 56

CHAPTER NO. 8 : COMPANY PROFILES 57

8.1. Lonza Group 57

8.1.1. Company Overview 57

8.1.2. Product Portfolio 57

8.1.3. Swot Analysis 57

8.1.4. Business Strategy 58

8.1.5. Financial Overview 58

8.2. Fuji Pharma Co., Ltd. 59

8.3. Kaken Pharmaceutical Co., Ltd. 59

8.4. JCR Pharmaceuticals Co., Ltd. 59

8.5. Daiichi Sankyo Company, Limited 59

8.6. Eisai Co., Ltd. 59

8.7. Ajinomoto Co., Inc. 59

8.8. CMIC Group 59

8.9. Sumitomo Dainippon Pharma Co., Ltd. 59

8.10. Nichirei Corporation 59

List of Figures

FIG NO. 1. Japan Contract Pharmaceutical Manufacturing Market Revenue, 2018 – 2032 (USD Million) 21

FIG NO. 2. Porter’s Five Forces Analysis for Japan Contract Pharmaceutical Manufacturing Market 27

FIG NO. 3. Company Share Analysis, 2023 28

FIG NO. 4. Company Share Analysis, 2023 29

FIG NO. 5. Company Share Analysis, 2023 29

FIG NO. 6. Company Share Analysis, 2023 30

FIG NO. 7. Japan Contract Pharmaceutical Manufacturing Market – Company Revenue Market Share, 2023 31

FIG NO. 8. Japan Contract Pharmaceutical Manufacturing Market Revenue Share, By Service Type, 2023 & 2032 37

FIG NO. 9. Market Attractiveness Analysis, By Service Type 38

FIG NO. 10. Incremental Revenue Growth Opportunity by Service Type, 2024 – 2032 38

FIG NO. 11. Japan Contract Pharmaceutical Manufacturing Market Revenue, By Service Type, 2018, 2023, 2027 & 2032 39

FIG NO. 12. Japan Contract Pharmaceutical Manufacturing Market for Contract Manufacturing Organization (CMO), Revenue (USD Million) 2018 – 2032 40

FIG NO. 13. Japan Contract Pharmaceutical Manufacturing Market for API Manufacturing, Revenue (USD Million) 2018 – 2032 42

FIG NO. 14. Japan Contract Pharmaceutical Manufacturing Market for Final dosage form manufacturing, Revenue (USD Million) 2018 – 2032 43

FIG NO. 15. Japan Contract Pharmaceutical Manufacturing Market for Packaging, Revenue (USD Million) 2018 – 2032 44

FIG NO. 16. Japan Contract Pharmaceutical Manufacturing Market for Contract Research Organization (CRO), Revenue (USD Million) 2018 – 2032 45

FIG NO. 17. Japan Contract Pharmaceutical Manufacturing Market for Drug Discovery, Revenue (USD Million) 2018 – 2032 46

FIG NO. 18. Japan Contract Pharmaceutical Manufacturing Market for Preclinical Studies, Revenue (USD Million) 2018 – 2032 47

FIG NO. 19. Japan Contract Pharmaceutical Manufacturing Market for Early Phase I-Ila, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. Japan Contract Pharmaceutical Manufacturing Market for Phase IIa-III, Revenue (USD Million) 2018 – 2032 49

FIG NO. 21. Japan Contract Pharmaceutical Manufacturing Market for Phase IIIb-IV, Revenue (USD Million) 2018 – 2032 50

FIG NO. 22. Japan Contract Pharmaceutical Manufacturing Market for Medical Coding and Writing, Revenue (USD Million) 2018 – 2032 51

FIG NO. 23. Japan Contract Pharmaceutical Manufacturing Market for Monitoring, Revenue (USD Million) 2018 – 2032 52

FIG NO. 24. Japan Contract Pharmaceutical Manufacturing Market for Clinical Data Management, Revenue (USD Million) 2018 – 2032 53

FIG NO. 25. Japan Contract Pharmaceutical Manufacturing Market for Others (Protocol Development, etc.), Revenue (USD Million) 2018 – 2032 54

List of Tables

TABLE NO. 1. : Japan Contract Pharmaceutical Manufacturing Market: Snapshot 20

TABLE NO. 2. : Drivers for the Japan Contract Pharmaceutical Manufacturing Market: Impact Analysis 23

TABLE NO. 3. : Restraints for the Japan Contract Pharmaceutical Manufacturing Market: Impact Analysis 25

TABLE NO. 4. : Japan Contract Manufacturing Organization (CMO) Japan Contract Pharmaceutical Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 41

TABLE NO. 5. : Japan Contract Manufacturing Organization (CMO) Japan Contract Pharmaceutical Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 41

TABLE NO. 6. : Japan Contract Pharmaceutical Manufacturing Market Revenue, By Service Type, 2018 – 2023 (USD Million) 55

TABLE NO. 7. : Japan Contract Pharmaceutical Manufacturing Market Revenue, By Service Type, 2024 – 2032 (USD Million) 55

TABLE NO. 8. : Japan Contract Pharmaceutical Manufacturing Market Revenue, By Molecule Type, 2018 – 2023 (USD Million) 56

TABLE NO. 9. : Japan Contract Pharmaceutical Manufacturing Market Revenue, By Molecule Type, 2024 – 2032 (USD Million) 56

Frequently Asked Questions

What is the current size of the Japan Contract Pharmaceutical Manufacturing market?

The Japan Contract Pharmaceutical Manufacturing market is valued at USD 17,246.92 million in 2023 and is projected to reach USD 36,963.23 million by 2032, growing at a compound annual growth rate (CAGR) of 8.83%.

What factors are driving the growth of the Japan Contract Pharmaceutical Manufacturing market?

Growth is driven by the increasing demand for cost-effective and high-quality drug production, the rise in outsourcing by pharmaceutical companies, Japan’s advanced technological infrastructure, and a skilled workforce. Additional drivers include the growing demand for biopharmaceuticals, stringent regulatory standards, and the adoption of advanced manufacturing technologies such as automation and artificial intelligence.

What are the key segments within the Japan Contract Pharmaceutical Manufacturing market?

The market is segmented by Service Type into Contract Manufacturing Organizations (CMO), including API manufacturing, final dosage form manufacturing, and packaging, and Contract Research Organizations (CRO), offering drug discovery, preclinical studies, and clinical trial management. By Molecule Type, it is divided into Small Molecules, which dominate due to their traditional applications, and Large Molecules, including biologics, which are rapidly growing due to rising demand for complex therapies.

What are some challenges faced by the Japan Contract Pharmaceutical Manufacturing market?

Challenges include navigating Japan’s stringent regulatory environment, high operational costs, labor shortages due to an aging workforce, and intense competition from both domestic and global players. These factors make it challenging to maintain cost-efficiency and adapt to evolving compliance requirements

Who are the major players in the Japan Contract Pharmaceutical Manufacturing market?

Key players include Lonza Group, Fuji Pharma Co., Ltd., Kaken Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Ajinomoto Co., Inc., CMIC Group, Sumitomo Dainippon Pharma Co., Ltd., and Nichirei Corporation. These companies drive market innovation, quality assurance, and technological advancements in pharmaceutical manufacturing.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –